Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

Trial Details

NCT ID
NCT04535271
Phase
PHASE2
Sponsor
Sarcoma Oncology Research Center, LLC
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Trabectedin
Locations (sample)
  • Santa Monica, California, United States|34.01949,-118.49138

Key Eligibility Criteria

  • Male or Female ≥ 18 years of age
  • Pathologically confirmed diagnosis of locally advanced, unresectable or metastatic leiomyosarcoma
  • Previously treated patient with measurable disease by RECIST v1.1
  • ECOG performance status ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →